Opendata, web and dolomites

MEDAS

MedAS: a Machine learning enabled Clinical Decision Support System to prevent prescription errors and improve patient safety

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEDAS project word cloud

Explore the words cloud of the MEDAS project. It provides you a very rough idea of what is the project "MEDAS" about.

team    medicines    financial    80    opportunity    issue    learning    otherwise    8b    machine    dramatically    alerts    enabled    generate    action    deploy    51    electronic    5b    analytics    first    fatal    failed    data    boy    8m    died    reaching    care    physician    burden    drug    founders    country    decision    enter    statistical    primary    estimate    list    accuracy    representing    2012    safety    proof    1m    feasibility    facilities    generation    simply    revenues    perspectives    error    public    2018    total    solutions    prototype    effectiveness    clinical    market    pull    retrospective    accidentally    found    medical    economic    constantly    prescribing    healthcare    medication    cdss    managed    outcomes    big    events    completely    realising    save       annual    missed    patient    became       2024    alerting    rates    prescription    innovative    21    medas    algorithms    roi    time    utilizes    errors    precise    wrong    nine       22    preventable    commercial    intend    adverse    identifies    theme    proven    depending    started    seize    platform    decided    outliers    solid    health    reducing    trials    usa    israel    medaware   

Project "MEDAS" data sheet

The following table provides information about the project.

Coordinator
MEDAWARE LTD 

Organization address
address: 10 ZARHIN ALEXANDER
city: RAANANA
postcode: 4366238
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.medaware.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDAWARE LTD IL (RAANANA) coordinator 50˙000.00

Map

 Project objective

Medication errors are the most common cause of adverse events in medication practice, although they are preventable. Only in Europe, prescription error rates range from 7.5% to 9.1% of the total managed medicines, representing a major public health issue, as some of those can even be fatal. They also represent a great economic burden to healthcare systems, with annual costs reaching €4.5B to €21.8B, depending on the country. MedAware’s founders decided to take action on the theme in 2012, when they found out that a nine-year-old boy died simply because his primary care physician accidentally selected the wrong drug, on his electronic prescribing pull-down list. By realising that current solutions completely failed to save this boy, the team started developing several proof-of-concept algorithms that became our first prototype and then MedAS (MedAware Alerting System). MedAS is an innovative patient-specific Clinical Decision Support System, that identifies and alerts on prescription errors in real-time, and with greater than 80% accuracy. It utilizes big-data analytics and advanced machine learning to identify statistical outliers and to generate precise alerts that would otherwise be missed by existing CDSS. MedAS’s effectiveness has already been proven both in retrospective trials and in real medical facilities in Israel and the USA: we improved patient safety, outcomes, and experience while dramatically reducing healthcare costs. Enabled by our next generation technology and given MedAS’s unique capabilities, we now intend to build a solid technology platform and to deploy it to the European market. The main objective of the feasibility study is to assess MedAS from technical, commercial and financial perspectives. We will seize the opportunity to enter the constantly growing CDSS market (€51.8M in Europe by 2018) with our novel technology and platform, and estimate revenues of €22.1M by 2024, with a ROI of 8.9

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

WIMUACT (2017)

TECHNOLOGY FOR THE IMPROVEMENT OF SPORTS PERFORMANCE IN NON-PROFESSIONAL CONTEXTS

Read More  

Revault (2015)

Revault - world´s first wearable private cloud. Securely sync and access your files from anywhere without an internet connection.

Read More  

Enterprise BIM (2017)

Enterprise BIM digitization platform feasibility verification

Read More